Skip to Main Content

Vivek Ramaswamy, the hedge fund manager turned biotech entrepreneur, was so confident he could make money from pharma drug castoffs, he named his new venture Roivant Sciences — the “Roi” being shorthand for return on investment.

Turns out, Ramaswamy meant his return on investment. Outside investors in Ramaswamy’s publicly traded “Vant” spinoffs are still waiting for their share.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.